Paliperidone STADA
Long-acting injectable atypical antipsychotic for schizophrenia – paliperidone palmitate once-monthly depot, 25 mg pre-filled syringe
Paliperidone STADA is a generic once-monthly long-acting injectable antipsychotic manufactured by STADA Arzneimittel AG, containing paliperidone palmitate, a depot ester of paliperidone. It is used for the maintenance treatment of schizophrenia in adults who have previously been stabilised on oral paliperidone or risperidone. By providing sustained dopamine and serotonin receptor modulation from a single intramuscular injection, Paliperidone STADA helps reduce the risk of relapse associated with missed oral doses. It is bioequivalent to the originator products Xeplion (European Union) and Invega Sustenna (United States) and is supplied as a pre-filled syringe containing paliperidone at strengths of 25, 50, 75, 100, or 150 mg. The 25 mg strength is primarily used for patients requiring low-dose maintenance, including those with severe renal impairment or heightened sensitivity to paliperidone.
Quick Facts: Paliperidone STADA
Key Takeaways
- Paliperidone STADA is a generic once-monthly intramuscular depot of paliperidone palmitate, used for maintenance treatment of schizophrenia in adults previously stabilised on oral paliperidone or risperidone.
- Initiation requires two deltoid injections (150 mg on day 1 and 100 mg on day 8, each ±4 days) to rapidly achieve therapeutic plasma levels, followed by monthly maintenance doses of 25 to 150 mg.
- The 25 mg strength is typically reserved for patients with severe renal impairment (creatinine clearance 10–50 mL/min) or those requiring low-dose maintenance due to tolerability concerns.
- Common adverse effects include weight gain, hyperprolactinaemia (breast enlargement, galactorrhoea, menstrual changes), extrapyramidal symptoms, injection site reactions, somnolence, and metabolic changes such as raised fasting glucose and lipids.
- Paliperidone STADA is therapeutically interchangeable with the originator products Xeplion (EU) and Invega Sustenna (US); brand-to-generic switching should be supervised by the treating psychiatrist to maintain clinical stability.
What Is Paliperidone STADA and What Is It Used For?
Paliperidone STADA belongs to the group of medicines known as atypical (second-generation) antipsychotics delivered in a long-acting injectable (LAI) formulation. The active substance, paliperidone palmitate, is an ester prodrug of paliperidone (9-hydroxyrisperidone), which is itself the major active metabolite of risperidone. Because paliperidone palmitate is poorly soluble in water, it forms a depot at the injection site, from which it is slowly hydrolysed by tissue esterases into free paliperidone. This sustained-release mechanism enables effective dopamine D2 and serotonin 5-HT2A receptor modulation from a single injection given every four weeks.
Paliperidone STADA is a generic product authorised by the European Medicines Agency and several national medicines agencies following demonstration of bioequivalence to the originator product, marketed internationally as Xeplion (European Union) and Invega Sustenna (United States and various other regions). Bioequivalence means that Paliperidone STADA produces essentially the same plasma paliperidone exposure over time when administered according to the same dosing schedule as the originator. In clinical practice, the generic formulation has the same indications, contraindications, warnings, dosing regimen and monitoring requirements as the originator product. STADA Arzneimittel AG is one of the largest generics manufacturers in Europe and produces multiple paliperidone palmitate strengths for community and inpatient psychiatric services.
The approved indication for Paliperidone STADA is the maintenance treatment of schizophrenia in adult patients. In the majority of regulatory jurisdictions, initiation with the long-acting injection requires that the patient has previously demonstrated tolerability and clinical response to oral paliperidone or oral risperidone. This prerequisite exists because, should an unexpected adverse reaction occur, a long-acting injectable cannot be withdrawn quickly; verifying oral tolerability first reduces the risk of prolonged exposure to a medication that a patient cannot tolerate.
Schizophrenia is a chronic severe mental illness affecting approximately 24 million people globally according to the World Health Organization (WHO). It is characterised by positive symptoms (hallucinations, delusions, thought disorder), negative symptoms (flat affect, social withdrawal, reduced motivation), and cognitive impairments. Long-acting injectable antipsychotics like Paliperidone STADA play a critical role in long-term management by addressing the single largest predictor of relapse: poor adherence to daily oral medication. Large real-world cohort studies and meta-analyses, including work published in The Lancet Psychiatry and JAMA Psychiatry, have shown that paliperidone palmitate LAIs significantly reduce rates of hospitalisation, relapse, and all-cause treatment discontinuation compared with oral antipsychotic regimens.
Some specialist guidelines also support the use of once-monthly paliperidone depots in selected patients with schizoaffective disorder or those requiring assisted treatment in forensic and community mental health settings. However, the exact licensed indications vary between regulatory regions, and any off-label use should be based on documented clinical judgement and institutional governance.
Paliperidone is a potent antagonist at dopamine D2 and serotonin 5-HT2A receptors. Blocking D2 receptors in the mesolimbic pathway reduces positive psychotic symptoms, while 5-HT2A antagonism mitigates the movement disorders typically associated with older (first-generation) antipsychotics. Paliperidone also blocks alpha-1 and alpha-2 adrenergic receptors (contributing to orthostatic hypotension) and H1 histamine receptors (contributing to somnolence).
What Should You Know Before Taking Paliperidone STADA?
Before initiating Paliperidone STADA, your psychiatrist will undertake a comprehensive assessment to determine whether the medicine is appropriate for you. This should include a detailed psychiatric and medical history, cardiovascular and metabolic risk assessment, medication review, and baseline laboratory investigations. Because the drug is released slowly over weeks after each injection, any adverse effect that emerges will take considerably longer to resolve than with oral formulations. Careful patient selection is therefore critical.
Contraindications
Paliperidone STADA should not be used in the following circumstances:
- Known hypersensitivity to paliperidone, risperidone, or any excipient of the formulation. Paliperidone is the active metabolite of risperidone, so cross-reactivity is expected.
- Children and adolescents under 18 years of age, because efficacy and safety of the long-acting injectable form have not been established in this population.
- Severe renal impairment where creatinine clearance is below 10 mL/min (end-stage renal disease). Paliperidone is predominantly excreted unchanged in urine and accumulates rapidly in severe renal failure.
- Comatose states or any severe central nervous system depression not related to the psychiatric illness itself.
- Known congenital long QT syndrome or documented history of serious cardiac arrhythmias, where the QT-prolonging effect of paliperidone could precipitate torsades de pointes.
Paliperidone is not approved for the treatment of dementia-related psychosis. Elderly patients with dementia treated with atypical antipsychotics show an increased risk of death and cerebrovascular events (stroke, transient ischaemic attack). This warning applies to all long-acting injectable paliperidone products including Paliperidone STADA.
Warnings and Precautions
Paliperidone STADA requires caution and additional monitoring in several clinical scenarios:
- Cardiovascular disease: Pre-existing heart failure, recent myocardial infarction, conduction disturbances, hypokalaemia, or hypomagnesaemia all increase the risk of arrhythmia. Baseline and follow-up ECG is prudent in these patients.
- Orthostatic hypotension: Paliperidone can cause a drop in blood pressure on standing, leading to dizziness and falls. Risk is highest in elderly patients, those with autonomic neuropathy, or those on antihypertensive therapy.
- Diabetes and metabolic syndrome: Atypical antipsychotics are associated with hyperglycaemia, weight gain, and dyslipidaemia. Baseline and periodic monitoring of weight, waist circumference, fasting glucose, HbA1c and lipid profile are recommended by most psychiatric societies.
- Seizure disorders: Paliperidone can lower the seizure threshold; use with caution in patients with epilepsy or known seizure risk factors.
- Parkinson’s disease or Lewy body dementia: These patients are at greater risk of neuroleptic malignant syndrome and severe extrapyramidal worsening, even at low doses.
- Prolactin-dependent tumours: Paliperidone is a strong prolactin elevator. Patients with known pituitary tumours or a history of breast cancer should use paliperidone only when no alternatives are suitable.
- Venous thromboembolism (VTE): All antipsychotics, including paliperidone, are associated with an increased risk of deep vein thrombosis and pulmonary embolism. Assess VTE risk factors (obesity, immobilisation, prior VTE) and discuss preventive strategies.
- History of priapism: Paliperidone’s alpha-1 antagonism can rarely cause priapism (a prolonged, painful erection), which is a urological emergency.
Paliperidone STADA must be administered by a healthcare professional trained in the correct intramuscular technique. Inadvertent intravenous injection or injection into subcutaneous tissue can alter absorption and cause local or systemic complications. Injection site pain, induration, swelling or bruising are common. Nodules or abscesses are rare but may occur with suboptimal technique.
Pregnancy and Breastfeeding
Paliperidone crosses the placenta. Neonates exposed to antipsychotics in the third trimester of pregnancy may experience extrapyramidal symptoms or withdrawal symptoms after delivery, including agitation, hypertonia or hypotonia, tremor, somnolence, respiratory distress, or feeding difficulties. These symptoms are usually self-limiting but may require neonatal observation.
The decision to use Paliperidone STADA during pregnancy should balance the maternal benefit of preventing relapse against the potential effects on the fetus. Relapse of severe psychiatric illness during pregnancy is itself associated with poor maternal and neonatal outcomes, so antipsychotic therapy is rarely stopped abruptly. Because the long-acting injectable cannot be withdrawn if pregnancy is unexpectedly diagnosed, planning pregnancy with a specialist team, and considering switching to an oral agent in advance, is ideal.
Paliperidone is excreted into breast milk in small amounts. The WHO and most neonatal formularies consider low-to-moderate dose paliperidone generally compatible with breastfeeding, provided the infant is observed for sedation, feeding difficulties, and extrapyramidal symptoms. Informed discussion with the treating psychiatrist and paediatrician is recommended.
Driving and Operating Machinery
Paliperidone can cause drowsiness, dizziness, blurred vision, and impaired reaction time. Patients should not drive or operate heavy machinery until they are confident that treatment does not impair their alertness. Risk is higher during initiation, after dose changes, or when paliperidone is combined with other sedating substances.
How Does Paliperidone STADA Interact with Other Drugs?
Paliperidone’s pharmacokinetic profile distinguishes it from many other atypical antipsychotics: roughly 60 percent of a dose is eliminated unchanged in urine, and hepatic metabolism accounts for only a minor pathway involving CYP3A4, CYP2D6, and non-CYP enzymatic hydrolysis. As a result, paliperidone is less affected by changes in CYP450 activity than, for example, risperidone or aripiprazole. Nonetheless, several clinically relevant interactions should be considered when initiating or modifying treatment.
Major Interactions
The interactions listed below are the most important to consider and often require dose adjustment, close monitoring, or a change of therapy:
| Interacting Drug / Class | Effect | Clinical Recommendation |
|---|---|---|
| Strong CYP3A4 / P-glycoprotein inducers (carbamazepine, rifampicin, phenytoin, St. John’s Wort) | Reduced plasma paliperidone concentrations; risk of subtherapeutic dosing and relapse | Re-evaluate paliperidone dose during co-treatment; avoid starting or stopping enzyme inducers while on stable depot therapy |
| QT-prolonging drugs (amiodarone, sotalol, quinidine, methadone, ondansetron, erythromycin, quinolones) | Additive QT prolongation and increased risk of torsades de pointes | Baseline and follow-up ECG; correct electrolyte imbalances; avoid combinations where possible |
| Levodopa and other dopamine agonists | Paliperidone may antagonise the therapeutic effect of dopaminergic treatment in Parkinson’s disease | Use the lowest effective paliperidone dose; monitor motor symptoms closely |
| Central nervous system depressants (opioids, benzodiazepines, alcohol, sedating antihistamines, gabapentinoids) | Additive sedation, respiratory depression, and cognitive impairment | Avoid unnecessary combinations; counsel regarding driving and operating machinery |
| Antihypertensive agents (alpha-blockers, diuretics, ACE inhibitors) | Potentiation of hypotensive effect; increased risk of falls | Monitor supine and standing blood pressure; adjust antihypertensive doses as needed |
| Metoclopramide and other dopamine antagonists | Additive extrapyramidal symptoms, neuroleptic malignant syndrome risk, and hyperprolactinaemia | Prefer alternative antiemetics (for example, ondansetron with ECG monitoring or domperidone with caution) |
Other Notable Interactions
Several additional interactions may require attention in selected patients:
- Oral risperidone or paliperidone: Patients should not routinely continue oral paliperidone or risperidone after initiating the depot, unless specifically advised during a planned cross-taper, because cumulative paliperidone exposure can become excessive.
- Lithium: No routine dose adjustment is needed, but monitoring for additive extrapyramidal symptoms and neurotoxicity is prudent, especially at higher lithium levels.
- Tramadol and bupropion: Additive seizure risk. Paliperidone already lowers the seizure threshold slightly; combining it with additional pro-convulsant drugs warrants caution in vulnerable patients.
- Anticholinergic medicines: Combining paliperidone with anticholinergic antiparkinsonian agents, some antihistamines, tricyclic antidepressants, or drugs for urinary incontinence can worsen constipation, dry mouth, urinary retention, and cognitive impairment.
- Serotonergic drugs: Although paliperidone itself is not considered serotonergic, combinations with SSRIs, SNRIs, MAO inhibitors, or tramadol should be monitored for rare serotonin-like toxicity.
- Injections near the pacemaker or indwelling device: When administering the depot in the deltoid muscle, avoid injecting on the same side as a pacemaker or port-a-cath device to reduce mechanical risk.
Unlike oral paliperidone, food has no effect on absorption of the depot. Alcohol consumption should be limited or avoided because of additive sedation and increased risk of falls. Smoking does not significantly affect paliperidone plasma concentrations (unlike clozapine or olanzapine), because paliperidone is not a substrate of CYP1A2. Caffeine in ordinary quantities has no clinically significant interaction.
What Is the Correct Dosage of Paliperidone STADA?
Dosing of Paliperidone STADA follows the same regimen as the originator paliperidone palmitate once-monthly products. The initiation schedule is designed to rapidly reach therapeutic plasma paliperidone concentrations so that bridging oral antipsychotic treatment is unnecessary in most patients. All doses must be administered by a trained healthcare professional using the pre-filled syringe supplied with the appropriate needle. The suspension must be shaken vigorously for at least 10 seconds immediately before injection to ensure a homogeneous suspension.
Adults (Schizophrenia – Standard Regimen)
| Phase | Dose | Timing | Injection Site |
|---|---|---|---|
| Initiation – Dose 1 | 150 mg | Day 1 | Deltoid muscle |
| Initiation – Dose 2 | 100 mg | Day 8 (±4 days) | Deltoid muscle (opposite side preferred) |
| Maintenance | 25–150 mg | Once every month (±7 days) | Deltoid or gluteal muscle (alternate sides) |
| Typical Maintenance Dose | 75 mg | Monthly, after 4 weeks of initiation | Deltoid or gluteal |
The maintenance dose is individually titrated based on clinical response, tolerability, and clinician judgement. Increases or decreases are generally made in 25 to 50 mg increments, with the understanding that steady-state plasma levels take several months to reach after a dose change because of the drug’s long apparent half-life. Dose adjustments during the initiation phase are discouraged unless absolutely necessary. A sustained reduction in efficacy despite adherence, or emergence of significant side effects, are the most common reasons to re-evaluate the dose.
When Is the 25 mg Strength Used?
The 25 mg pre-filled syringe of Paliperidone STADA has specific, relatively narrow clinical use cases:
- Severe renal impairment (creatinine clearance 10–49 mL/min): Because paliperidone is cleared almost entirely by the kidneys, patients with significantly reduced renal function need substantially lower doses. In moderate to severe renal impairment, the recommended initiation is 75 mg on day 1 and 25 mg on day 8, followed by a 50 mg monthly maintenance dose, with 25 mg reserved for those who cannot tolerate higher levels.
- Heightened sensitivity to paliperidone: Elderly patients and those with multiple comorbidities sometimes require low-dose maintenance to maintain efficacy while minimising sedation, orthostatic hypotension, or extrapyramidal effects.
- Cross-taper from oral risperidone at low doses: Patients previously stabilised on very low doses of oral risperidone (for example, 1–2 mg daily) may be maintained on correspondingly low paliperidone palmitate doses, where the 25 mg strength provides the appropriate monthly depot quantity.
- Consolidation phase after dose reduction: Occasionally, after a patient has done well on a higher maintenance dose for several years, clinicians and patients agree to a stepwise reduction. The 25 mg strength provides a lower step before potential discontinuation discussions.
Renal Impairment
Because paliperidone is predominantly excreted unchanged in urine, renal function strongly influences dosing:
Mild Renal Impairment (CrCl 50–79 mL/min)
Initiation: 100 mg on day 1 and 75 mg on day 8, both in the deltoid muscle. Monthly maintenance: 50 mg, adjusted individually within the range of 25 to 100 mg depending on response and tolerability.
Moderate to Severe Renal Impairment (CrCl 10–49 mL/min)
Initiation: 75 mg on day 1 and 25 mg on day 8 (deltoid). Monthly maintenance: 50 mg, adjusted individually between 25 and 50 mg. The 25 mg strength is particularly relevant in this population.
End-Stage Renal Disease (CrCl <10 mL/min) or Haemodialysis
Paliperidone STADA is not recommended in patients with CrCl below 10 mL/min because the medicine accumulates and there is limited clinical data.
Elderly Patients
In elderly patients with normal renal function, standard dosing is used but with enhanced vigilance for falls, orthostatic hypotension, and cognitive side effects. Many elderly patients have age-related decline in creatinine clearance despite a normal serum creatinine; calculating estimated glomerular filtration rate (eGFR) or creatinine clearance is essential before selecting the starting dose. As highlighted in the warnings section, Paliperidone STADA must not be used in elderly patients whose psychosis is secondary to dementia.
Children and Adolescents
Safety and efficacy of Paliperidone STADA have not been established in patients below 18 years of age, and the medicine is not recommended for use in this age group. Early-onset schizophrenia requiring a long-acting injectable is generally managed with specialist input and specific paediatric formulations where available.
Missed Dose
Because the depot releases drug over several weeks, delayed doses are less likely to cause immediate subtherapeutic gaps than missed oral doses, but prolonged delays remain clinically significant and may require a modified re-initiation regimen:
- Day 8 initiation dose delay up to 4 days: Can be administered as soon as possible.
- Day 8 initiation dose delay 4–7 days: Administer as soon as possible and contact the prescriber to adjust further dosing.
- Monthly maintenance delay up to 6 weeks: Resume the usual monthly dose as soon as possible.
- Monthly maintenance delay 6 weeks to 6 months: Typically requires a re-loading regimen with two deltoid doses approximately one week apart before returning to the monthly schedule.
- Monthly maintenance delay over 6 months: Usually requires complete restart of the initiation regimen.
Overdose
Because Paliperidone STADA is administered by a healthcare professional, overdose is rare. However, accidental administration of an inappropriately large dose, or accumulation in renal impairment, can cause excessive sedation, severe extrapyramidal symptoms, QT prolongation, hypotension, seizures, or coma. Treatment is symptomatic and supportive, with airway protection, cardiac and ECG monitoring, and standard measures for hypotension and arrhythmia. Dialysis is not useful because paliperidone is extensively bound to tissue. Contact emergency services or a poison control centre without delay.
What Are the Side Effects of Paliperidone STADA?
Like all antipsychotic medicines, paliperidone can cause a spectrum of side effects that vary in frequency and severity. Because Paliperidone STADA is a long-acting formulation, any adverse effect may persist for weeks after the last injection until the depot is fully absorbed and eliminated. The side-effect profile of paliperidone depots mirrors that of oral paliperidone, with the addition of injection-site reactions, and has been extensively characterised in double-blind randomised controlled trials, open-label long-term extension studies, and post-authorisation pharmacovigilance databases.
The following frequencies are drawn from the summaries of product characteristics of paliperidone palmitate long-acting injectables approved by the European Medicines Agency and the US Food and Drug Administration, and are consistent with the published literature on Paliperidone STADA and bioequivalent generics.
Very Common
May affect more than 1 in 10 people
- Insomnia and disturbed sleep
- Headache
- Injection site pain, swelling, or induration
Common
May affect up to 1 in 10 people
- Weight gain
- Increased appetite
- Somnolence and sedation
- Dizziness and orthostatic hypotension
- Anxiety, agitation, or restlessness
- Akathisia (inner restlessness with need to move)
- Extrapyramidal symptoms (tremor, rigidity, bradykinesia, dystonia)
- Elevated serum prolactin and related effects (galactorrhoea, breast enlargement, menstrual irregularities, sexual dysfunction)
- Dry mouth and constipation
- Nausea, vomiting, abdominal pain or discomfort
- Tachycardia, palpitations
- Hypertension
- Increased hepatic transaminases
- Fatigue and asthenia
- Back pain and musculoskeletal pain
Uncommon
May affect up to 1 in 100 people
- Tardive dyskinesia (involuntary movements, especially of face and tongue)
- Neuroleptic malignant syndrome (rare but potentially life-threatening)
- Seizures (convulsions)
- Diabetes mellitus or worsening of pre-existing diabetes
- Hyperglycaemia, dyslipidaemia, increased triglycerides and cholesterol
- Venous thromboembolism (deep vein thrombosis, pulmonary embolism)
- QT prolongation on ECG
- Syncope (fainting)
- Urinary incontinence or retention
- Dysphagia (difficulty swallowing)
- Pneumonia, including aspiration pneumonia
- Allergic reactions (rash, pruritus, angioedema)
- Injection site abscess, haemorrhage, or cyst
Rare or Frequency Not Known
Reported in clinical trials or post-marketing surveillance
- Priapism (prolonged painful erection – urological emergency)
- Agranulocytosis, neutropenia, leucopenia, or thrombocytopenia
- Diabetic ketoacidosis in susceptible individuals
- Severe skin reactions including DRESS syndrome (drug reaction with eosinophilia and systemic symptoms)
- Anaphylactic reaction
- Cerebrovascular events (stroke, transient ischaemic attack), particularly in elderly patients with dementia-related psychosis
- Sudden unexplained death
- Intestinal obstruction, ileus, faecal impaction
- Rhabdomyolysis
- Floppy infant syndrome and neonatal withdrawal when used in pregnancy
- Intraoperative floppy iris syndrome (IFIS) in patients undergoing cataract surgery
Call emergency services or seek urgent medical review if you experience any of the following: high fever with muscle stiffness, confusion, sweating, and altered consciousness (possible neuroleptic malignant syndrome); sudden uncontrollable facial, tongue, or limb movements (possible tardive dyskinesia); sudden chest pain, breathlessness, or leg swelling (possible thromboembolism); severe allergic reaction with facial swelling or difficulty breathing; a prolonged painful erection lasting more than four hours (priapism); or any new thoughts of self-harm.
In elderly patients with dementia-related psychosis, paliperidone palmitate — like other atypical antipsychotics — is associated with an increased number of deaths and cerebrovascular events. Paliperidone STADA is therefore contraindicated in this population regardless of the severity of agitation or behavioural disturbance.
Reporting suspected adverse drug reactions is an essential part of post-authorisation pharmacovigilance. Patients, carers, and clinicians are encouraged to report any suspected side effect to their national pharmacovigilance authority, either directly or through their healthcare provider. Ongoing reporting allows continuous re-evaluation of the benefit-risk balance of long-acting injectable antipsychotics.
How Should You Store Paliperidone STADA?
Correct storage and handling of Paliperidone STADA are essential to preserve the integrity of the aqueous nanocrystal suspension and ensure consistent drug release after injection. Because the product is typically stored, prepared, and administered in healthcare facilities rather than by patients at home, most of these responsibilities fall on pharmacy and nursing staff. However, patient and caregiver awareness is still valuable, particularly for transport between pharmacy and clinic.
- Temperature: Store below 30 degrees Celsius (86 degrees Fahrenheit). The product should not be refrigerated unless specifically stated in the local product information, and it must never be frozen.
- Light protection: Keep the pre-filled syringe in its original carton until immediately before use to protect from light.
- Handling: Shake the syringe vigorously for at least 10 seconds immediately before injection to ensure a homogeneous suspension. Do not use if clumping, foreign particles, discolouration, or cracks in the syringe are observed.
- Needle selection: Use only the needles supplied with the pre-filled syringe, selected according to injection site (deltoid or gluteal) and patient body weight, as specified in the product information.
- Disposal: Any unused medicine, used syringes, or needles must be disposed of in compliance with local sharps and pharmaceutical waste regulations. Do not flush down the toilet or place in household waste.
- Expiry date: Do not use Paliperidone STADA after the expiry date stated on the outer carton and syringe label. The expiry date refers to the last day of the stated month.
Community pharmacies that dispense Paliperidone STADA to depot clinics should confirm with the treating team whether any additional temperature-controlled transport precautions are required, particularly during hot weather. Delayed or interrupted cold-chain management, although not strictly required for this product, should still be avoided to maintain best practice with aqueous nanosuspensions.
What Does Paliperidone STADA Contain?
The active substance in Paliperidone STADA is paliperidone palmitate, a highly lipophilic fatty-acid ester of paliperidone. After intramuscular injection, paliperidone palmitate forms a slow-release depot at the injection site, from which tissue esterases gradually hydrolyse the ester bond to release free paliperidone. Paliperidone is chemically identical to the major active metabolite of risperidone (9-hydroxyrisperidone) and was originally developed as a standalone oral extended-release tablet (Invega) before being reformulated as a palmitate ester for depot use. Paliperidone STADA is a generic of the originator paliperidone palmitate once-monthly injectable.
Active Ingredient Content Per Pre-Filled Syringe
| Strength (paliperidone) | Equivalent paliperidone palmitate | Injection volume |
|---|---|---|
| 25 mg | 39 mg | 0.25 mL |
| 50 mg | 78 mg | 0.5 mL |
| 75 mg | 117 mg | 0.75 mL |
| 100 mg | 156 mg | 1.0 mL |
| 150 mg | 234 mg | 1.5 mL |
Inactive Ingredients (Excipients)
The sterile aqueous suspension typically contains the following excipients, which function as surfactants, viscosity modifiers, buffers, and tonicity agents:
- Polysorbate 20 – surfactant that stabilises the nanosuspension
- Polyethylene glycol 4000 – viscosity-modifying agent
- Citric acid monohydrate – buffering agent
- Disodium hydrogen phosphate anhydrous – buffering agent
- Sodium dihydrogen phosphate monohydrate – buffering agent
- Sodium hydroxide – for pH adjustment
- Water for injections – solvent
Paliperidone STADA contains less than 1 mmol (23 mg) of sodium per dose, which means it is essentially sodium-free — relevant for patients on a sodium-restricted diet. The product contains neither gluten nor lactose. Patients with a known allergy to any listed excipient should discuss alternatives with their prescriber. The appearance of the suspension is white to off-white; any sign of foreign particles, discolouration or abnormal clumping after shaking should prompt disposal and replacement of the syringe.
Frequently Asked Questions About Paliperidone STADA
Paliperidone STADA is a once-monthly long-acting injection. After the two-dose initiation regimen on day 1 and day 8, maintenance injections are given once every month (every 28 days, with a tolerance window of plus or minus 7 days). This monthly schedule makes it a convenient option for patients who have difficulty remembering daily oral antipsychotic medication. For patients who have been stable on paliperidone palmitate once monthly for at least four months, a switch to a three-monthly paliperidone palmitate depot may be considered, but this is a separate medicine and requires specialist evaluation.
Paliperidone STADA and the originator products Xeplion (European Union) and Invega Sustenna (United States) all contain the same active ingredient, paliperidone palmitate, at the same strengths in aqueous nanosuspension for once-monthly intramuscular injection. They are considered bioequivalent under regulatory definitions, meaning they deliver essentially the same paliperidone exposure over time when used according to the same dosing schedule. Clinical effects, side effects, and safety precautions are therefore the same. Switching between brand and generic formulations should still be supervised by the treating psychiatrist, particularly for patients clinically stable on a specific product.
The 25 mg strength is primarily used for maintenance treatment in patients who require a low paliperidone dose. The most common indications are moderate to severe renal impairment (creatinine clearance 10 to 49 millilitres per minute), where standard doses would accumulate and cause toxicity, and elderly patients or patients with multiple comorbidities who have demonstrated sensitivity to higher doses. The 25 mg strength may also be used at the end of a gradual dose reduction when a patient and clinician agree to step down before a potential discontinuation discussion.
If the second initiation dose on day 8 is delayed by up to 4 days, it can still be given as soon as possible without modification. Longer delays during initiation typically require a tailored re-initiation plan. For monthly maintenance doses, delays of less than 6 weeks usually allow the patient to resume the regular dose. Delays between 6 weeks and 6 months often require a re-loading regimen in the deltoid muscle before returning to the normal monthly schedule. Delays longer than 6 months require restarting the full initiation regimen. Contact the treating psychiatric team immediately if an injection is missed, because interrupted treatment is a major risk factor for relapse.
Weight gain is a well-recognised side effect of paliperidone and can occur with Paliperidone STADA, although typically less pronounced than with olanzapine or clozapine. Clinical trials have shown that approximately 9 to 17 percent of patients gain 7 percent or more of their baseline weight after 12 months of treatment. Regular monitoring of weight, waist circumference, fasting blood glucose, HbA1c, and lipid profile is recommended throughout treatment. Lifestyle interventions, including nutritional advice and physical activity, should be incorporated into the care plan from the start. If significant metabolic change occurs, a switch to a more weight-neutral antipsychotic such as aripiprazole may be considered.
Yes. Paliperidone is a strong dopamine D2 antagonist in the tuberoinfundibular pathway and commonly elevates serum prolactin. This can cause breast enlargement, galactorrhoea (milk production) in men and women, menstrual irregularity or amenorrhoea, reduced libido, or erectile dysfunction. Persistent hyperprolactinaemia can also contribute to reduced bone mineral density over time. Prolactin-related symptoms should be discussed with the prescriber, as dose reduction, switching to a more prolactin-sparing antipsychotic such as aripiprazole, or endocrine referral may be appropriate. Baseline and periodic prolactin measurement may be considered in symptomatic patients.
Alcohol should be avoided or strictly limited while on Paliperidone STADA. Alcohol adds to the sedating and cognitive effects of paliperidone, increases the risk of falls due to orthostatic hypotension, and can worsen the underlying psychiatric condition. It may also interact with concomitant medications such as benzodiazepines or mood stabilisers. Patients with a concurrent alcohol or substance use disorder should discuss an integrated treatment plan with their mental health team, as untreated comorbid substance use is strongly associated with poor long-term outcomes.
Switching requires a planned cross-taper under the supervision of a psychiatrist. A common approach is to confirm that the patient tolerates a therapeutic dose of oral paliperidone or risperidone for at least several weeks, and then start the initiation regimen (150 mg on day 1 and 100 mg on day 8 in the deltoid) while gradually tapering the oral antipsychotic. Because the initiation regimen is designed to reach therapeutic plasma paliperidone concentrations quickly, no oral supplementation is usually required after day 8. Exact switching protocols vary based on the patient’s previous dose, response, and tolerability.
References
- European Medicines Agency (EMA). Xeplion (paliperidone palmitate) – Summary of Product Characteristics. Last updated 2025. Available at: www.ema.europa.eu/en/medicines/human/EPAR/xeplion
- U.S. Food and Drug Administration (FDA). Invega Sustenna (paliperidone palmitate) Prescribing Information. Reference ID: 4897645. Available at: www.accessdata.fda.gov
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Geneva: WHO; 2023.
- National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 2024.
- Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview. CNS Drugs. 2021;35(1):39-59. doi:10.1007/s40263-020-00779-5
- Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387-404. doi:10.1016/S2215-0366(21)00039-0
- Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomised, double-blind, placebo-controlled study. Schizophr Res. 2010;116(2-3):107-117. doi:10.1016/j.schres.2009.10.026
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962. doi:10.1016/S0140-6736(13)60733-3
- Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686-693. doi:10.1001/jamapsychiatry.2017.1322
- British National Formulary (BNF). Paliperidone. NICE Evidence Services. Updated 2025. Available at: bnf.nice.org.uk/drugs/paliperidone
Editorial Team
Medical Content
iMedic Medical Editorial Team – Specialists in Psychiatry and Clinical Pharmacology with documented academic background and clinical experience in long-acting injectable antipsychotics.
Medical Review
iMedic Medical Review Board – Independent panel of physicians who verify medical accuracy, evidence quality, and adherence to international guidelines (WHO, EMA, FDA, NICE, BNF).
Evidence Standard
Level 1A evidence based on systematic reviews, meta-analyses, and randomised controlled trials. GRADE evidence framework applied. No commercial funding.
Accessibility
Content reviewed for WCAG 2.2 Level AAA compliance. Optimised for screen readers, keyboard navigation, and assistive technology. High contrast support enabled.
Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.